Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sleep Disorders Channel is supported through educational grants from Alkermes and Takeda.

VJNeurology is an independent medical education platform. Channel supporters have no influence over the production of content.

Share this video  

Sleep Europe 2026 | Ketamine in narcolepsy type 1: promising preclinical findings and potential added benefit for mood

François Ricordeau, MD, University Hospital of Lyon, Lyon, France, discusses preclinical research on ketamine as a potential treatment for narcolepsy type 1 (NT1), emphasizing that it is still far from therapeutic application. Dr Ricordeau highlights its potential additional effect on mood, given ketamine’s antidepressant properties, which could make it relevant for patients with NT1 and comorbid depressive symptoms, particularly those who do not tolerate, or only partially respond to, current treatments. This interview took place at Sleep Europe 2026, which was held in Maastricht, Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.